Hepion Pharmaceuticals' stock rockets after upbeat results of preclinical study of liver cirrhosis treatment [MarketWatch]
Hepion Pharmaceuticals, Inc. (HEPA)
Last hepion pharmaceuticals, inc. earnings: 11/14 05:17 pm
Check Earnings Report
Company Research
Source: MarketWatch
Hepion Pharmaceuticals' stock rockets after upbeat results of preclinical study of liver cirrhosis treatment Shares of Hepion Pharmaceuticals Inc. HEPA, +57.93% rocketed 57% in active trading to pace all premarket gainers, after the biopharmceutical company announced positive results from a preclinical study of its CRV431 liver cirrhosis treatment. Trading volume topped 836,000 shares, already more than half the full-day average of about 1.5 million shares. The company said late Wednesday that CRV431 prevented the development of liver cirrhosis in a "highly aggressive" model of liver disease. "The results align with previous findings in other experimental models and highlight the tremendous potential of CRV431 as a treatment for liver diseases, including NASH, where progression to cirrhosis is a primary medical concern," said Chief Executive Robert Foster. The stock had plunged 88% year to date through Wednesday, while the iShares Nasdaq Biotechnology ETF IBB, -0.25% had climbed
Show less
Read more
Impact Snapshot
Event Time:
HEPA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HEPA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HEPA alerts
High impacting Hepion Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
HEPA
News
- Model Medicines Appoints Dr. Launa Aspeslet as Senior Scientific & Clinical Advisor [Yahoo! Finance]Yahoo! Finance
- Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH' Trial [Yahoo! Finance]Yahoo! Finance
- Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ TrialGlobeNewswire
- Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell [Yahoo! Finance]Yahoo! Finance
- Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael PurcellGlobeNewswire
HEPA
Earnings
- 11/20/23 - Miss
HEPA
Sec Filings
- 4/16/24 - Form 10-K
- 4/1/24 - Form NT
- 3/7/24 - Form 4
- HEPA's page on the SEC website